Nuveen LLC Invests $16.99 Million in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Nuveen LLC has made a significant investment in Kiniksa Pharmaceuticals, acquiring 765,054 shares worth approximately $16.99 million, which represents about 1.05% of the company's stock.
• Several institutional investors have also increased their stakes in Kiniksa, leading to hedge funds collectively owning 53.95% of the company.
• Kiniksa Pharmaceuticals reported a net revenue of $156.80 million for the last quarter, surpassing analysts’ expectations, while its stock currently has an average target price of $41.17 according to several research analysts.

Nuveen LLC acquired a new stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 765,054 shares of the company's stock, valued at approximately $16,992,000. Nuveen LLC owned 1.05% of Kiniksa Pharmaceuticals International as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in KNSA. Braidwell LP raised its position in Kiniksa Pharmaceuticals International by 19.3% during the fourth quarter. Braidwell LP now owns 3,452,447 shares of the company's stock worth $68,289,000 after acquiring an additional 557,934 shares during the last quarter. Vanguard Group Inc. raised its position in Kiniksa Pharmaceuticals International by 4.7% during the first quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company's stock worth $74,606,000 after acquiring an additional 151,604 shares during the last quarter. Nuveen Asset Management LLC raised its position in Kiniksa Pharmaceuticals International by 7.3% during the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock worth $15,737,000 after acquiring an additional 54,361 shares during the last quarter. Millennium Management LLC raised its position in Kiniksa Pharmaceuticals International by 50.9% during the fourth quarter. Millennium Management LLC now owns 779,672 shares of the company's stock worth $15,422,000 after acquiring an additional 263,146 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Kiniksa Pharmaceuticals International by 3.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock worth $15,262,000 after acquiring an additional 29,300 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Stock Performance

Kiniksa Pharmaceuticals International stock traded up $0.53 during trading on Tuesday, reaching $33.57. The company had a trading volume of 584,624 shares, compared to its average volume of 672,465. Kiniksa Pharmaceuticals International, plc has a 12-month low of $17.82 and a 12-month high of $34.55. The stock's 50 day moving average price is $29.98 and its two-hundred day moving average price is $25.72. The firm has a market capitalization of $2.49 billion, a price-to-earnings ratio of 839.46 and a beta of 0.14.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The firm had revenue of $156.80 million during the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Insider Activity at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, Director Thomas Malley sold 78,233 shares of the business's stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $33.09, for a total transaction of $2,588,729.97. Following the completion of the sale, the director directly owned 12,546 shares in the company, valued at $415,147.14. The trade was a 86.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Michael R. Megna sold 17,000 shares of the business's stock in a transaction that occurred on Monday, August 4th. The stock was sold at an average price of $32.35, for a total transaction of $549,950.00. Following the sale, the chief accounting officer owned 33,041 shares of the company's stock, valued at approximately $1,068,876.35. This represents a 33.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 655,532 shares of company stock valued at $20,622,436 over the last quarter. Company insiders own 53.48% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on KNSA. Wedbush restated an "outperform" rating and set a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Wells Fargo & Company lifted their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 9th. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 2nd. Finally, Jefferies Financial Group lifted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research report on Tuesday, July 29th. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $41.17.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.